| pubmed-article:7480237 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:7480237 | lifeskim:mentions | umls-concept:C0008976 | lld:lifeskim |
| pubmed-article:7480237 | lifeskim:mentions | umls-concept:C0677616 | lld:lifeskim |
| pubmed-article:7480237 | lifeskim:mentions | umls-concept:C0038941 | lld:lifeskim |
| pubmed-article:7480237 | lifeskim:mentions | umls-concept:C0052796 | lld:lifeskim |
| pubmed-article:7480237 | lifeskim:mentions | umls-concept:C0178602 | lld:lifeskim |
| pubmed-article:7480237 | lifeskim:mentions | umls-concept:C0023981 | lld:lifeskim |
| pubmed-article:7480237 | lifeskim:mentions | umls-concept:C0205171 | lld:lifeskim |
| pubmed-article:7480237 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:7480237 | pubmed:dateCreated | 1995-12-15 | lld:pubmed |
| pubmed-article:7480237 | pubmed:abstractText | Over a 9-month period from September of 1991 to May of 1992, 339 patients were included in a randomized, double-blind, placebo-controlled study using azithromycin as the prophylactic agent to determine whether it effects a clinically meaningful reduction in postoperative surgical infections in plastic surgery. Azithromycin was given as prophylaxis in 171 patients and placebo in 168 patients. The study medication was a single oral dose taken at 8 P.M. the day before surgery. The patients were followed up for a minimum of 4 weeks after surgery. The patients who received wound infection prophylaxis had 5.1 percent infections compared with 20.5 percent in the placebo group (p = 0.00009). Eighty percent of all wound infections were first seen after discharge, explaining why plastic surgeons might overlook their infectious complications. There was a significant reduction in postoperative complications (p = 0.04) and in the additional use of antibiotics postoperatively (p = 0.007) in the prophylaxis group. Subgroup analysis showed a significant reduction in surgical infections in breast surgery (p < 0.05) and reconstructive surgery with flaps (p < 0.05). No effect of the prophylactic regime was demonstrated in patients undergoing secondary surgery for cleft lip and palate disease. | lld:pubmed |
| pubmed-article:7480237 | pubmed:language | eng | lld:pubmed |
| pubmed-article:7480237 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7480237 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:7480237 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7480237 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7480237 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:7480237 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:7480237 | pubmed:issn | 0032-1052 | lld:pubmed |
| pubmed-article:7480237 | pubmed:author | pubmed-author:SandsmarkMM | lld:pubmed |
| pubmed-article:7480237 | pubmed:author | pubmed-author:GierckskyK... | lld:pubmed |
| pubmed-article:7480237 | pubmed:author | pubmed-author:LingaasEE | lld:pubmed |
| pubmed-article:7480237 | pubmed:author | pubmed-author:AbyholmFF | lld:pubmed |
| pubmed-article:7480237 | pubmed:author | pubmed-author:SamdalFF | lld:pubmed |
| pubmed-article:7480237 | pubmed:author | pubmed-author:AmlandP FPF | lld:pubmed |
| pubmed-article:7480237 | pubmed:author | pubmed-author:AndenaesKK | lld:pubmed |
| pubmed-article:7480237 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:7480237 | pubmed:volume | 96 | lld:pubmed |
| pubmed-article:7480237 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:7480237 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:7480237 | pubmed:pagination | 1378-83 | lld:pubmed |
| pubmed-article:7480237 | pubmed:dateRevised | 2011-2-16 | lld:pubmed |
| pubmed-article:7480237 | pubmed:meshHeading | pubmed-meshheading:7480237-... | lld:pubmed |
| pubmed-article:7480237 | pubmed:meshHeading | pubmed-meshheading:7480237-... | lld:pubmed |
| pubmed-article:7480237 | pubmed:meshHeading | pubmed-meshheading:7480237-... | lld:pubmed |
| pubmed-article:7480237 | pubmed:meshHeading | pubmed-meshheading:7480237-... | lld:pubmed |
| pubmed-article:7480237 | pubmed:meshHeading | pubmed-meshheading:7480237-... | lld:pubmed |
| pubmed-article:7480237 | pubmed:meshHeading | pubmed-meshheading:7480237-... | lld:pubmed |
| pubmed-article:7480237 | pubmed:meshHeading | pubmed-meshheading:7480237-... | lld:pubmed |
| pubmed-article:7480237 | pubmed:meshHeading | pubmed-meshheading:7480237-... | lld:pubmed |
| pubmed-article:7480237 | pubmed:meshHeading | pubmed-meshheading:7480237-... | lld:pubmed |
| pubmed-article:7480237 | pubmed:meshHeading | pubmed-meshheading:7480237-... | lld:pubmed |
| pubmed-article:7480237 | pubmed:meshHeading | pubmed-meshheading:7480237-... | lld:pubmed |
| pubmed-article:7480237 | pubmed:meshHeading | pubmed-meshheading:7480237-... | lld:pubmed |
| pubmed-article:7480237 | pubmed:year | 1995 | lld:pubmed |
| pubmed-article:7480237 | pubmed:articleTitle | A prospective, double-blind, placebo-controlled trial of a single dose of azithromycin on postoperative wound infections in plastic surgery. | lld:pubmed |
| pubmed-article:7480237 | pubmed:affiliation | Department of Plastic Surgery, Norwegian National Hospital, Oslo, Norway. | lld:pubmed |
| pubmed-article:7480237 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:7480237 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:7480237 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:7480237 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7480237 | lld:pubmed |
